Gemcitabine + Carboplatin in Breast Cancer

Breast Cancer Clinical Trial

Official title:

Gemcitabine Plus Carboplatin in Patients With Pretreated Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00450762
• Other study ID #: Gem/Carbo MUC01
• Status: Completed
• Phase: Phase 2
• First received: March 20, 2007
• Last updated: March 21, 2007
• Start date: March 2004
• Est. completion date: October 2006

Study information

• Verified date: March 2007
• Source: Ludwig-Maximilians - University of Munich
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The rational for this trial is given by the knowledge that gemcitabine acts as a potent inhibitor of DNA repair and therefore may prevent adequate repair of platin-induced DNA damage. Gemcitabine is an excellent choice for combination therapy by its unique mechanism of action and favourable toxicity profile. The combination of gemcitabine and cisplatin was shown to be effective in several trials, producing response rates of 30-52 % in patients with pretreated metastatic breast cancer. To improve on tolerability and handling of the regime carboplatin may be the more appropriate choice for treatment. The mechanism of action of carboplatin is very similar to that of cisplatin. The rational for combining gemcitabine and carboplatin is based on their single-agent activities in metastatic breast cancer, the activity of this combination in other malignancies and on the fact that carboplatin has demonstrated efficacy comparable with cisplatin in several tumor types.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: October 2006
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed metastatic breast cancer

• All patients were required to give written informed consent.

• Prior treatment with chemotherapy, hormonal therapy, immunotherapy or local radiotherapy was allowed (except gemcitabine or platinum agents).

• Patients were required to have at least one bidimensionally measurable lesion outside a previous radiation port.

• Age = 18 years

• Karnofsky Performance status = 70 %

• Minimal life expectancy of 12 weeks

• Adequate haematological, renal, cardiac and hepatic function:

1. Leukocyte count = 3.0 x 109/l

2. Absolute neutrophil count = 2.0 x 109/l

3. Platelet count = 100 x 109/l

4. Haemoglobin = 8 g/dl

5. Total serum bilirubin = 1.25 x upper limit of normal (ULN) In presence of liver metastasis = 3 x ULN

6. Transaminase (ALT,AST) level = 3 x ULN In presence of liver metastasis = 5 x ULN

7. Alkaline phosphatase level = 2.5 x ULN

8. Creatinine clearance was required to exceed 60 ml/min.

Exclusion Criteria:

• Prior treatment with gemcitabine or platinum agents

• Inadequate creatinine clearance (< 60 ml/min)

• Only bone metastases

• Symptomatic brain metastases

• Women who are pregnant, lactating or refuse effective contraception

• Secondary malignancy

• History of another primary malignant disease other than in situ carcinoma of the uterine cervix or adequately treated basal cell skin cancer

• Active infection

• Any other concomitant severe clinical condition making implementation of the protocol including pre-hydration difficult.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• gemcitabine

• carboplatin

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Ludwig-Maximilians - University of Munich	Eli Lilly and Company